Hybrigenics Unveils a Lead Chemical Structure for Its Discovery of New Anticancer Drugs
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Hybrigenics (ALHYG), a bio-pharmaceutical company, announces the publication of a scientific article in Molecular Cancer Therapeutics showing the anticancer potential of HBX 41,108, its lead small molecule inhibitor of ubiquitin-specific protease no.7 (USP7).
Many cancer types from different organs are dependent on the crucial tumor-suppressor protein called p53, which is regulated by USP7. The article published in Molecular Cancer Therapeutics describes how Hybrigenics has demonstrated that small molecules can inhibit USP7 activity, resulting in the activation of functional p53 and in the growth inhibition of p53-dependent cancer cell lines.
HBX 41,108 is the lead compound of such USP7 inhibitors, with a demonstrated potential to become an innovative anticancer drug candidate after further chemical optimization.
Molecular Cancer Therapeutics is a highly-ranked international scientific journal accepting articles for publication after an academic peer-reviewed process with stringent acceptance criteria for novelty, relevance to the field and strength of experimental evidence.
"This publication highlights the recognition by the scientific community of our pioneer research position in the field of USP inhibition", said Frédéric Colland, Head of Biological Research at Hybrigenics.
Many cancer types from different organs are dependent on the crucial tumor-suppressor protein called p53, which is regulated by USP7. The article published in Molecular Cancer Therapeutics describes how Hybrigenics has demonstrated that small molecules can inhibit USP7 activity, resulting in the activation of functional p53 and in the growth inhibition of p53-dependent cancer cell lines.
HBX 41,108 is the lead compound of such USP7 inhibitors, with a demonstrated potential to become an innovative anticancer drug candidate after further chemical optimization.
Molecular Cancer Therapeutics is a highly-ranked international scientific journal accepting articles for publication after an academic peer-reviewed process with stringent acceptance criteria for novelty, relevance to the field and strength of experimental evidence.
"This publication highlights the recognition by the scientific community of our pioneer research position in the field of USP inhibition", said Frédéric Colland, Head of Biological Research at Hybrigenics.
